BCL2L11 is altered in 0.33% of lung adenocarcinoma patients [2].

BCL2L11 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2L11 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is altered in 1.73% of lung adenocarcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK4 is altered in 3.86% of lung adenocarcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 26.09% of lung adenocarcinoma patients [2].

EGFR is an inclusion eligibility criterion in 12 clinical trials for lung adenocarcinoma, of which 9 are open and 3 are closed. Of the trials that contain EGFR status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 2 are phase 3 (1 open) [3].

ERBB2 is altered in 4.32% of lung adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for lung adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [3].

HRAS is altered in 0.4% of lung adenocarcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is altered in 32.84% of lung adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 7 clinical trials for lung adenocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain KRAS status and lung adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [3].

MET is altered in 4.95% of lung adenocarcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 1.13% of lung adenocarcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK1 is altered in 3.91% of lung adenocarcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is altered in 1.99% of lung adenocarcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 5.59% of lung adenocarcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 3.36% of lung adenocarcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 4.01% of lung adenocarcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STK11 is altered in 12.75% of lung adenocarcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 45.24% of lung adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].